| Literature DB >> 31505793 |
Abstract
A wide variety of viruses exploit furin and other proprotein convertases (PCs) of the constitutive protein secretion pathway in order to regulate their cell entry mechanism and infectivity. Surface proteins of enveloped, as well as non-enveloped, viruses become processed by these proteases intracellularly during morphogenesis or extracellularly after egress and during entry in order to produce mature virions activated for infection. Although viruses also take advantage of other proteases, it is when some viruses become reactive with PCs that they may develop high pathogenicity. Besides reacting with furin, some viruses may also react with the PCs of the other specificity group constituted by PC4/PC5/PACE4/PC7. The targeting of PCs for inhibition may result in a useful strategy to treat infections with some highly pathogenic viruses. A wide variety of PC inhibitors have been developed and tested for their antiviral activity in cell-based assays.Entities:
Keywords: furin; proprotein convertases; protease inhibitors; proteases
Mesh:
Substances:
Year: 2019 PMID: 31505793 PMCID: PMC6784293 DOI: 10.3390/v11090837
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Families of pathogenic viruses that are PC dependent. Many families of viruses exploit the host-cell PCs to regulate their cell entry mechanism.
| Familiy | Virus | Capsid | Genome |
|---|---|---|---|
|
| HPV | Naked | Circular dsDNA |
|
| Herpes, Cytomegalovirus, Epstein-Barr, Varicella-zoster | Enveloped | Linear dsDNA |
|
| Dengue, Zika, Yellow fever, West Nile | Enveloped | Linear ssRNA+ |
|
| Chikungunya, Semliki forest | Enveloped | Linear ssRNA+ |
|
| MERS | Enveloped | Linear ssRNA+ |
|
| HIV, Leukemia viruses | Enveloped | Linear ssRNA−-RT |
|
| Hepatitis B | Enveloped | Linear ssDNA−-RT |
|
| Ebola, Marburg | Enveloped | Linear ssRNA− |
|
| Measles, RSV, Newcastle disease, Nipah | Enveloped | Linear ssRNA− |
|
| Avian influenza H5N1 | Enveloped | Linear ssRNA− |
Figure 1X-ray crystal structure of human furin. The PC catalytic domain (red) shared by all PCs has the structural fold typical of the subtilin family of serine proteases. The position of the catalytic triad residues is marked in cyan. The P domain (blue) regulates catalytic activity. The PCs differ in their additional domains. PDB ID code 5JXH.
PC cleavage site motifs in the coat proteins L1 and L2 of HPV types. The cleavage site numbers correspond to those in the HPV16 sequences. The P4Arg and P1Arg residues are denoted in red.
PC cleavage site motifs in the glycoprotein B of herpes viruses. A highly variable loop in the viral glycoprotein B (residues in blue) contains PC cleavage site motifs (P4Arg and P1Arg residues are red). HHSV, human herpes simplex virus; SHSV, suid herpes simplex virus; GHSV, gallid herpes simplex virus; CpHSV, caprine herpes simplex virus; CaHSV, canid herpes simples virus; BHSV, bovine herpes simplex virus; EHSV, equide herpes simplex virus; EBV, Epstein-Barr virus; VZV, varicella-zoster virus; HCMV, human cytomegalovirus; PRV, pseudorabies virus.
Alignment of flavivirus PC cleavage sites.
Figure 2X-ray crystal structure of the HIV-1 envelope pg160 glycoprotein monomer. The fusion machine is composed of three gp160 monomers which are divided into N-terminal gp120 (green) and C-terminal pg41 (gray). Residue in red denotes the end of gp120 and residue in blue the beginning of gp41 after PC cleavage. PDB ID code 6MTJ.
Figure 3X-ray crystal structure of the HA trimer from the influenza virus A type H5. Each HA monomer is divided into HA1 (red, blue, and gray) and HA2 (oarange, cyan, and white, respectively) subunits after the PC cleavage denoted by residues at the end HA1 (yellow) and the beginning of HA2 (purple). PDB ID code 2IBX.
Cleavage loop in the HA protein of influenza viruses. The variable region is blue with the arrow denoting the cleavage site. The P4Arg and P1Arg residues are colored red.
Inhibitors of PCs tested for their antiviral activity in cell-based assays of viral propagation.
| Inhibitors | Viruses | References |
|---|---|---|
| SKI-1 inhibitors | LCMV, LASV | [ |
| Peptides and peptidomimetics | CHIKV, SFV | [ |
| Polyarginines | HIV | [ |
| Macrocyclic peptides | RSV | [ |
| α1PDX | MV | [ |